ASCO 2019 | KEYNOTE-029: pembrolizumab with ipilimumab for melanoma

Georgina Long

Georgina Long, MD, PhD, FRACP, of The University of Sydney, Sydney, Australia, discusses results from the KEYNOTE-029 trial, used to determine the safety and tolerability of pembrolizumab in combination with ipilimumab melanoma treatment. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video